-
11/05/2014
PAION's partner Ono decides not to file for regulatory approval of Remimazolam in Japan and will return its Remimazolam rights for Japan to PAION
-
10/10/2014
PAION expects ONO's Remimazolam decision on filing in Japan in November 2014
-
09/24/2014
PAION AG grants license to YichangHumanwell for M6G in China
-
07/17/2014
PAION completes private placement with Pendopharm's european affiliate pharmascience international limited through the issuance of new shares in a placement volume of EUR 4 million
-
07/04/2014
PAION AG will successfully place capital increase
-
06/18/2014
PAION AG starts capital increase with subscription rights through the issue of 18.5 million shares at EUR 2.50 per share
-
06/17/2014
PAION grants licence for “Mena Region" to R-Pharm
-
06/13/2014
PAION grants Pendopharm exclusive option to Remimazolam in Canada
-
05/28/2014
PAION reports positive Phase II results of its short acting anaesthetic Remimazolam in major cardiac surgery
-
04/11/2014
PAION AG plans capital increase with subscription rights by issuing up to 18.5 million shares to fund the Remimazolam programmes required for approval in the US and EU
-
02/12/2014
PAION completes private placement through the issuance of new shares in a placement volume of EUR 3.17 million
-
01/16/2014
PAION AG plans to issue up to 2.5 million shares in a private placement